IBDEI1SF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29929,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,29929,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,29929,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,29930,0)
 ;;=D06.1^^135^1372^41
 ;;^UTILITY(U,$J,358.3,29930,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29930,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,29930,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,29930,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,29931,0)
 ;;=D06.7^^135^1372^39
 ;;^UTILITY(U,$J,358.3,29931,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29931,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,29931,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,29931,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,29932,0)
 ;;=D04.9^^135^1372^42
 ;;^UTILITY(U,$J,358.3,29932,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29932,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,29932,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,29932,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,29933,0)
 ;;=C91.11^^135^1372^45
 ;;^UTILITY(U,$J,358.3,29933,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29933,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,29933,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,29933,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,29934,0)
 ;;=C91.10^^135^1372^46
 ;;^UTILITY(U,$J,358.3,29934,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29934,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,29934,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,29934,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,29935,0)
 ;;=C92.11^^135^1372^47
 ;;^UTILITY(U,$J,358.3,29935,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29935,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,29935,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,29935,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,29936,0)
 ;;=C92.10^^135^1372^48
 ;;^UTILITY(U,$J,358.3,29936,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29936,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,29936,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,29936,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,29937,0)
 ;;=D47.1^^135^1372^49
 ;;^UTILITY(U,$J,358.3,29937,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29937,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,29937,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,29937,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,29938,0)
 ;;=C82.69^^135^1372^50
 ;;^UTILITY(U,$J,358.3,29938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29938,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,29938,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,29938,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,29939,0)
 ;;=C82.60^^135^1372^51
 ;;^UTILITY(U,$J,358.3,29939,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29939,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,29939,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,29939,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,29940,0)
 ;;=D56.2^^135^1372^52
 ;;^UTILITY(U,$J,358.3,29940,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29940,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,29940,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,29940,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,29941,0)
 ;;=D75.9^^135^1372^53
 ;;^UTILITY(U,$J,358.3,29941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29941,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,29941,1,4,0)
 ;;=4^D75.9
